In “Changes in Bone Mineral Density after Antiretroviral Initiation with Tenofovir Disoproxil Fumarate-Emtricitabine plus Atazanavir-Ritonavir, Darunavir-Ritonavir, or Raltegravir [J Infect Dis. 2015 Oct 15;212(8):1241–9.] by Brown et al. there are three errors noted by the authors:
Lines 176–180 Corrected sentence should read:
The following monocyte cell phenotypes were characterized and expressed as percentages: classical phenotype (CD14+CD16-), intermediate phenotype (CD14+CD16+), non-classical phenotype (CD14dimCD16+). CD4+ and CD8+ T cells with activated (HLA-DR+CD38+), senescent (CD28-CD57+) or senescent and exhausted (CD28-CD57+PD1+) phenotypes were assessed.
Lines 279–282 Corrected sentence should read:
Associations of monocyte subpopulations (% MNC: CD14+CD16+, % MNC: CD14dimCD16+) with bone loss at either the lumbar spine or the total hip or were also not consistently detected (data not shown).
Table 1.
Subject Characteristics at Baseline
| ATV/r (n=109) | RAL (n=106) | DRV/r (n=113) | |
|---|---|---|---|
| Age (y) | 37 (31,45) | 36 (27,44) | 35 (27,46) |
| Sex | 91% M, 9% F | 89% M,11% F | 89% M,11% F |
| Race/ethnicity† | 49% W, 31% B, 18% H | 41% W, 32% B, 19% H | 42% W, 33% B, 22% H |
| Weight (kg) | 80 (69,88) | 77 (66,89) | 77(67,83) |
| Body Mass Index (kg/m 2) | 26 (23, 29) | 24 (22,28) | 24 (22, 27) |
| Concomitant Medications affecting Bone* | 22% | 22% | 20% |
| Current Smoking | 40% | 37% | 36% |
| CD4+ cell count (/mm 3) | 350 (211, 461) | 343 (207,461) | 355(207, 461) |
| HIV-1 RNA (log 10 c/mL) | 4.62 (4.05, 5.10) | 4.52 (4.13, 5.08) | 4.52 (3.95, 4.95) |
| hsCRP (mg/L) | 1.45 (0.71, 3.16) | 1.35 (0.69, 2.8) | 1.17 (0.66, 2.95) |
| IL-6 (pg/mL) | 1.82 (1.20, 2.69) | 1.55 (1.07, 3.02) | 1.78 (1.20, 2.75) |
| sIL-2R (pg/ml) | 1862 (1479, 2291) | 1820 (1202, 2344) | 1660 (1202, 2239) |
| sCD14 (ng/ml) | 1778 (1413, 2138) | 1698 (1445, 1950) | 1660 (1445, 2042) |
| sCD163 (ng/ml) | 1148 (813, 1585) | 1230 (832, 1585) | 1023 (741, 1548) |
| OPG (pmol/L) | 3.89 (3.16, 4.90) | 3.98 (3.31, 4.68) | 4.47 (3.63, 5.25) |
| RANK L (pg/ml) | 35.5 (16.9, 58.9) | 26.9 (11.2, 53.7) | 24.5 (11.2, 49.0) |
| N=101 | N=95 | N=101 | |
| % CD4(+): CD28(-) CD57(+) | 4.8 (2.2, 9.9) | 5.2 (2.0, 11.3) | 5.3 (2.6, 9.3) |
| % CD4(+): CD28(-) CD57(+) PD1(+) | 0.03 (0.01, 0.07) | 0.03 (0.01, 0.07) | 0.03 (0.01, 0.06) |
| % CD8(+): CD28(-) CD57(+) | 23.0 (16.9, 30.5) | 25.9 (18.6, 30.9) | 22.9 (18.4, 30.5) |
| % CD8(+): CD28(-) CD57(+) PD1(+) | 0.07 (0.05, 0.12) | 0.08 (0.05, 0.16) | 0.09 (0.04, 0.14) |
| % CD4(+): CD38(+) HLADR(+) | 19.0 (11.9, 30.3) | 19.4 (12.0, 32.2) | 17.4 (10.3, 26.3) |
| % CD8(+): CD38(+) HLADR(+) | 41.7 (34.8, 55.2) | 44.7 (37.0, 53.7) | 42.5 (33.2, 53.2) |
| % MNC: CD14dimCD16+ | 0.7 (0.4, 1.7) | 0.7 (0.2, 1.9) | 0.9 (0.3, 1.6) |
| % MNC: CD14+CD16+ | 9.7 (5.9, 13.8) | 9.7 (5.0, 13.1) | 9.0 (5.7, 11.7) |
Values represent median (Q1,Q3) or percent; † W: white; B: black; H:hispanic; remaining represents other
*includes androgen, anticonvulsants, proton pump inhibitors, corticosteroids, estrogens, SSRIs
Deleted the 2 rows that show data related to: % MNC: CD14 (hi) CD16 (hi) and % MNC: CD14 (low)CD16 (hi). Replaced with 2 new rows that show data related to: % MNC: CD14dimCD16+ and % MNC: CD14+CD16+. The corrected table is reproduced below.
The authors regret these errors.